特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リキッドバイオプシー (液体生検) の世界市場:2020年~2028年

Global Liquid Biopsy Market Forecast 2020-2028

発行 Inkwood Research 商品コード 947605
出版日 ページ情報 英文 248 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
リキッドバイオプシー (液体生検) の世界市場:2020年~2028年 Global Liquid Biopsy Market Forecast 2020-2028
出版日: 2020年07月27日 ページ情報: 英文 248 Pages
概要

世界のリキッドバイオプシー (液体生検) 市場は、2020年~2028年の予測期間中に、CAGRで20.50%の成長が予測されています。市場の成長を促進する要因として、精密医療の成長、政府の取り組みの急増、高齢者におけるがんの増加、液体生検の可能性の増加、技術の進歩が挙げられます。

当レポートでは、世界のリキッドバイオプシー (液体生検) 市場について調査分析し、市場概要、市場力学、セグメント別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 調査範囲と調査手法

第2章 エグゼクティブサマリー

第3章 市場力学

  • 市場の定義
  • 主要促進要因
  • 主要抑制要因

第4章 主要アナリティクス

  • ポーターのファイブフォース分析
  • 主要なイニシアチブ
  • 規制の枠組み
  • 機会マトリクス
  • ベンダー情勢
  • 主な投資考察

第5章 市場:治療適応別

  • 肺がん
  • 乳がん
  • 前立腺がん
  • 大腸がん
  • 悪性黒色腫
  • その他の種類のがん
  • 腫瘍以外の適応

第6章 市場:臨床応用別

  • 治療モニタリング
  • 予後・再発モニタリング
  • 治療選択
  • 診断・スクリーニング

第7章 市場:バイオマーカーの種類別

  • 核酸
  • タンパク質
  • 細胞外小胞
  • 細胞

第8章 市場:解析プラットフォーム別

  • NGS
  • マイクロアレイ
  • PCR
  • プロテオミクス
  • その他

第9章 市場:解析目的別

  • 早期発見/スクリーニング
  • 治療ガイダンス
  • モニタリング
  • 診断

第10章 市場:循環バイオマーカー別

  • 循環腫瘍DNA(ctDNA)
  • 循環腫瘍細胞(CTC)
  • Cell-free DNA(cfDNA)
  • その他

第11章 市場:エンドユーザー別

  • 医師の研究室
  • 病院
  • 臨床診断検査室

第12章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • ベルギー
    • ポーランド
    • その他の欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア・ニュージーランド
    • タイ
    • インドネシア
    • ベトナム
    • その他のアジア太平洋地域
  • その他の世界の地域
    • ラテンアメリカ
    • 中東・アフリカ

第13章 企業プロファイル

  • BECTON DICKINSON AND COMPANY (BD)
  • F HOFFMANN-LA ROCHE
  • BIO-RAD LABORATORIES INC
  • B BRAUN MELSUNGEN AG
  • BOSTON SCIENTIFIC CORPORATION
  • QIAGEN NV
  • PLANMECA OY
  • COOK MEDICAL INC
  • AD-TECH MEDICAL INSTRUMENT CORP
  • AGILENT TECHNOLOGIES INC
  • ARGON MEDICAL DEVICES INC
  • CINTEC MEDICAL LTD
  • FISCHER MEDICAL TECHNOLOGIES LLC
  • IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - LIQUID BIOPSY
  • TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
  • TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
  • TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
  • TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 23: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 25: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 26: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 27: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 28: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2019
  • FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2019
  • FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2020-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2020-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2019
  • FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2020-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2020-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2020-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2019
  • FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2020-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2020-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2020-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2020-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2019
  • FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2020-2028 (IN $ MILLION)
  • FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2020-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2020-2028 (IN $ MILLION)
  • FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2019
  • FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2020-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2020-2028 (IN $ MILLION)
  • FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2020-2028 (IN $ MILLION)
  • FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2020-2028 (IN $ MILLION)
  • FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2019
  • FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS' OFFICE LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2020-2028 (IN $ MILLION)
  • FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 44: THE UNITED STATES LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 47: THE UNITED KINGDOM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 55: ASIA PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 64: REST OF ASIA PACIFIC LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
目次
Product Code: 16840

KEY FINDINGS

The global liquid bioscopy market is predicted to register a CAGR of 20.50% during the forecast period of 2020 to 2028. The primary factors propelling the market growth are growth in precision medicine, rising government initiatives, the growing pervasiveness of cancer in the older population, increasing potential of liquid biopsies, and technological advancements.

MARKET INSIGHTS

Due to rapid changes in consumer demands, diagnostic testing has been shifted from hospitals and commercial laboratories, to locations closer to the patient's home. This has resulted in minimizing the overall cost of testing. Most healthcare services in urban areas are delivered at home with a reduced focus on rural areas. Moreover, developing countries also have a high percentage of people residing in rural areas, with very few diagnostic centers and low accessibility. Thus, fatalities due to cancer are very high in rural environments. The increasing death toll can be attributed to a lack of awareness of the disease, leading to ignorance of diagnosis and treatment. Hence, it is anticipated that improved diagnostic tools, faster response times, easy availability of biopsy solutions at an inexpensive rate, and high amounts of research grants would lead to establishing numerous diagnostic centers, especially in rural areas and developing countries in the region. Consequently, the growing number of diagnostic centers are projected to offer a lucrative opportunity for biopsy solution providers and augment market growth.

REGIONAL INSIGHTS

Countries across the Asia Pacific, North America, Europe, and the rest of the world are analyzed to assess global liquid biopsy market growth. According to Inkwood Research, North America is estimated to garner the largest revenue share by the end of the forecast period. As a result of the increasing number of cancer cases, the demand for liquid biopsy in North America is projected to rise. Canada and the United States have superior biopsy technologies that specialize in detecting diseases at the early stages, thus reducing the countries' mortality rates.

COMPETITIVE INSIGHTS

As the global liquid biopsy market continues to emerge, regular and rapid developments are being witnessed. There are very few obstructions to innovations entering the market, resulting in medium to high levels of industry rivalry. Some of the established companies in the market include Cook Medical Inc, F Hoffmann-La Roche, Qiagen NV, Planmeca OY, Boston Scientific Corporation, Bio-Rad Laboratories, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISING GOVERNMENT INITIATIVES
    • 3.2.2. GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
    • 3.2.3. GROWING NUMBER OF DIAGNOSTIC CENTERS
    • 3.2.4. GROWTH OF PRECISION MEDICINE
    • 3.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • 3.2.6. RISING POTENTIAL OF THE LIQUID BIOPSY
    • 3.2.7. TECHNOLOGICAL ADVANCEMENT
  • 3.3. KEY RESTRAINTS
    • 3.3.1. LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
    • 3.3.2. POOR COMPENSATION STRUCTURES
    • 3.3.3. HIGH COST OF THE TEST
    • 3.3.4. LACK OF REIMBURSEMENT
    • 3.3.5. LACK OF SKILLED PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. KEY LIQUID BIOPSY INITIATIVES
  • 4.3. REGULATORY FRAMEWORK
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. LUNG CANCER
  • 5.2. BREAST CANCER
  • 5.3. PROSTATE CANCER
  • 5.4. COLORECTAL CANCER
  • 5.5. MELANOMA CANCER
  • 5.6. OTHER TYPES OF CANCER
  • 5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION

  • 6.1. TREATMENT MONITORING
  • 6.2. PROGNOSIS AND REOCCURRENCE MONITORING
  • 6.3. TREATMENT SELECTION
  • 6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE

  • 7.1. NUCLEIC ACID
  • 7.2. PROTEIN
  • 7.3. EXTRACELLULAR VESICLES
  • 7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM

  • 8.1. NGS
  • 8.2. MICROARRAY
  • 8.3. PCR
  • 8.4. PROTEOMICS
  • 8.5. OTHER ANALYSIS PLATFORMS

9. MARKET BY ANALYSIS PURPOSE

  • 9.1. EARLY DETECTION/SCREENING
  • 9.2. THERAPY GUIDANCE
  • 9.3. MONITORING
  • 9.4. DIAGNOSIS

10. MARKET BY PRODUCT

  • 10.1. CIRCULATING TUMOR DNA (CTDNA)
  • 10.2. CIRCULATING TUMOR CELLS (CTCS)
  • 10.3. CELL-FREE DNA (CFDNA)
  • 10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER

  • 11.1. PHYSICIANS' OFFICE LABORATORIES
  • 11.2. HOSPITALS
  • 11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. THE UNITED STATES
    • 12.1.2. CANADA
  • 12.2. EUROPE
    • 12.2.1. THE UNITED KINGDOM
    • 12.2.2. FRANCE
    • 12.2.3. GERMANY
    • 12.2.4. ITALY
    • 12.2.5. RUSSIA
    • 12.2.6. BELGIUM
    • 12.2.7. POLAND
    • 12.2.8. REST OF EUROPE
  • 12.3. ASIA PACIFIC
    • 12.3.1. JAPAN
    • 12.3.2. CHINA
    • 12.3.3. INDIA
    • 12.3.4. SOUTH KOREA
    • 12.3.5. AUSTRALIA & NEW ZEALAND
    • 12.3.6. THAILAND
    • 12.3.7. INDONESIA
    • 12.3.8. VIETNAM
    • 12.3.9. REST OF ASIA PACIFIC
  • 12.4. REST OF WORLD
    • 12.4.1. LATIN AMERICA
    • 12.4.2. MIDDLE EAST & AFRICA

13. COMPANY PROFILES

  • 13.1. BECTON DICKINSON AND COMPANY (BD)
  • 13.2. F HOFFMANN-LA ROCHE
  • 13.3. BIO-RAD LABORATORIES INC
  • 13.4. B BRAUN MELSUNGEN AG
  • 13.5. BOSTON SCIENTIFIC CORPORATION
  • 13.6. QIAGEN NV
  • 13.7. PLANMECA OY
  • 13.8. COOK MEDICAL INC
  • 13.9. AD-TECH MEDICAL INSTRUMENT CORP
  • 13.10. AGILENT TECHNOLOGIES INC
  • 13.11. ARGON MEDICAL DEVICES INC
  • 13.12. CINTEC MEDICAL LTD
  • 13.13. FISCHER MEDICAL TECHNOLOGIES LLC
  • 13.14. IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL